Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Creative Mind of Yossi Gross, Medical Device Inventor

This article was originally published in Start Up

Executive Summary

Yossi Gross has founded, so far, 17 medical device start-ups across a broad spectrum of industry segments and has more than 300 patents. He's created companies in diabetes, gastroenterology, stroke, ophthalmology, asthma, congestive heart failure, remote patient monitoring, and urology. START-UP spoke with Gross, to learn the secret of his inventiveness, and what gets him up in the morning.

You may also be interested in...



Xenia's Public-Private Blend Fosters Early-Stage Medtech

Israel's Xenia Venture Capital is an early-stage technology incubator with an unusual model for getting medical technologies out of the nest and on the wing.

Changing Minds at the FDA

Visioncare's recent success in getting an FDA advisory panel to change a recommendation is a rare and noteworthy achievement. But the agency could prove to be an even more formidable barrier - and a potential catalyst for change - for the device sector going forward.

Rainbow Medical: Entrepreneurial Efficiency in Medical Devices

One of Israel's most prolific medical device entrepreneurs, Yossi Gross has launched an amazing number of companies in a wide array of clinical spaces. Two years ago, Gross and GlenRock Israel came up with the idea for Rainbow Medical, a new approach to creating companies around the technologies Gross develops. Rainbow is neither quite a venture fund nor a US-style incubator but has aspects of both. Rainbow's point: too many fledgling device companies have to spend their time raising money rather than developing their technology, while the founders have little experience in doing so or in building the company once capital comes in. Rainbow's innovative investment-fund strategy addresses both issues.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel